Hospital Acquired Infection Control Market was valued at $29.1 billion in 2021 and is forecasted to reach $31.3 billion by 2026, growing at a 1.5% CAGR. This growth is driven by increasing hospital-acquired infections, more surgeries, an aging population, and rising chronic diseases. Technological advances in sterilization equipment and awareness of hygiene due to COVID-19 also contribute. The market sees high growth potential with the use of E-beam sterilization and outsourcing to emerging markets, despite challenges like the cost of endoscope reprocessing and limited reimbursement.
The growth of the hospital acquired infection control market can largely be attributed to factors such as the high incidence of hospital-acquired infections, the increasing number of surgical procedures, the growing geriatric population and the increasing incidence of chronic diseases, technological advancements in sterilization equipment, and the growing awareness of environmental & personal hygiene due to COVID-19. The increasing use of E-beam sterilization, reintroduction of ethylene oxide sterilization, and the growing healthcare industry and outsourcing of operation to emerging countries are expected to offer high-growth opportunities for market players during the forecast period.
Currently, with the surge in COVID-19 cases, there is an increasing focus on personal hygiene along with the increasing production of medical nonwovens and single-use products such as face masks and gloves. This is further expected to drive the growth of the market in the coming years. On the other hand, concerns regarding the safety of reprocessed instruments are expected to limit market growth to some extent in the coming years. This, along with factors such as the high cost of endoscope reprocessing and limited reimbursement in developing countries and end-user noncompliance with sterilization standards, is expected to restrain the growth of this market.
The sterilization segment is expected to grow at the highest CAGR during the forecast period
Based on the products and services used in the control of HAIs, the hospital acquired infection control market is segmented into sterilization, disinfectors, endoscope reprocessing products, disinfectants, protective barriers, and other infection control products. The sterilization segment is expected to grow at the highest CAGR during the forecast period. This is attributed to the growing incidence of chronic diseases and pandemics (such as COVID-19), the increasing need to reduce surgical-site infections (SSIs), and the growing number of surgeries performed worldwide. Increasing initiatives and regulatory actions taken by governments in various countries to fortify hospitals with essential infection control standards to prevent the spread of HAIs are also expected to support market growth.
The hospitals & ICUs segment is expected to account for the largest share of the hospital acquired infection control market
Based on end user, the market has been segmented into hospitals & intensive care units (ICUs), ambulatory surgical and diagnostic centers, nursing homes and maternity centers, and other end users (dental clinics, trauma centers, and clinical laboratories). The hospitals & ICUs segment accounted for the largest share of the market in 2020. Growth in this market is majorly attributed to the rising prevalence of HAIs, increasing adoption of single-use medical devices, and rising number of surgical procedures worldwide.
The Asia Pacific hospital infection control market is expected to grow at the highest CAGR from 2021 to 2026. Most of the growth in the market is expected from the emerging countries across the Asia Pacific. The rising number of surgical procedures conducted annually, favorable government regulations, the large patient population, and the rising incidence of COVID-19 are expected to drive the growth of the APAC market during the forecast period.
The key players operating in the hospital acquired infection control market include STERIS plc (US), Sotera Health Company (US), Getinge AB (Sweden), Advanced Sterilization Products (ASP) (US), Ecolab Inc. (US), 3M Company (US), MATACHANA GROUP (Spain), MMM Group (Germany), Belimed AG (Switzerland), Reckitt Benckiser (UK), Metrex Research LLC (UK), Miele Group (Germany), Pal International (UK), MELAG Medizintechnik GmbH & Co. KG (Germany), Contec, Inc. (US), MEDALKAN (Greece), Systec GmbH (Germany), C.B.M. S.r.l. Medical Equipment (Italy), Continental Equipment Company (US), and BGS Beta-Gamma-Service GmbH & Co. KG (Germany).
Recent Developments of Hospital Acquired Infection Control Industry
- In 2021, STERIS acquired Cantel, a global provider of infection prevention products and services, through a US subsidiary, to diversify its vast portfolio of sterilization services.
- In 2021, Sterigenics S.A.S., a subsidiary of Sotera Health Company, expanded its ethylene oxide (EO) facility located in Rantigny, France, thereby increasing its European sterilization capacity.
- In 2020, Getinge launched the Getinge Solsus 66 steam sterilizer for hospitals and surgical instruments with increased capacity and operational reliability compared to other sterilizers
- In 2020, Sotera Health Company acquired Iotron, a key outsourced provider of E-beam sterilization services in North America. This acquisition helped expand its electron beam (E-beam) footprint and added new expertise to its Sterigenics business.
- In 2020, STERIS completed the acquisition of Key Surgical, a global provider of sterile processing, operating room, and endoscopy products. This acquisition enhanced the company’s product offering and STERIS’ revenue by 35%.
- In 2020, 3M partnered with Cummins to increase the production of high-efficiency particulate filters for use in 3M’s powered air-purifying respirators (PAPRs) due to the surge in demand for personal protective equipment due to the COVID-19 outbreak
Content Source:
https://www.marketsandmarkets.com/PressReleases/hospital-acquired-infection-control.asp